Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation
- 1 December 1994
- journal article
- Published by Frontiers Media SA in Transplant International
- Vol. 7 (s1) , 7-10
- https://doi.org/10.1111/j.1432-2277.1994.tb01301.x
Abstract
The steroid-paring effect and the use of concomitant medication during the treatment of liver transplant patients with the novel immunosuppressant FK 506 were evaluated within the European multicentre, randomized, parallel-group study in liver transplantation. Patients undergoing primary liver transplantation were randomized to treatment with FK 506 (n= 267) or with a cyclosporin-based immunosuppressive regimen (n= 273). The total cumulative steroid usage was significantly reduced in the FK 506 treatment group, which is likely to have resulted from the lower incidence of acute rejection in these patients. The number of patients receiving antidiabetic, diuretic and antihypertensive therapy did not differ between the two treatment groups, even though the incidence of diabetes mellitus and oliguria was significantly higher in the FK 506 group. It can, therefore, be assumed that in a number of such cases the severity of these events was very mild necessitating no specific therapy.Keywords
This publication has 3 references indexed in Scilit:
- Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipientsTransplant International, 1994
- Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre studyTransplant International, 1994
- FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATIONThe Lancet, 1989